A major lesson from the COVID-19 pandemic is the need to decolonize transnational governance so that the world is better able to handle both future and current global crises.
Academic rigor, journalistic flair
Articles on COVAX
Displaying 1 - 20 of 46 articles
Only 15.8% of the population in low-income countries is double-dosed. Vaccine hoarding by high income countries is to blame.
From vaccines to treatments and even medical equipment, intellectual property rights have hampered the world’s efforts to fight the pandemic.
In places with low vaccination rates, COVID-19 has the chance to linger, and variants develop and travel. Without global vaccine equity, this entirely predictable pattern will repeat itself.
The new variant is a warning: unless we take urgent action to correct global vaccine inequities, we risk the emergence of further variants, some of which may evade vaccines.
Afrigen will be a technology transfer and training hub: it shares technology and develops skills specifically around how to produce a safe, effective and affordable mRNA vaccine.
Vaccine donations are unsustainable and often inefficient to scale. They are a temporary solution to a systemic issue.
The vaccine-sharing initiative is still without its biggest donor – India – while rich countries are diverting spare doses towards youth and booster programmes.
Each dose of Pfizer has a long and complex path involving mixing, storage at temperatures colder than the South Pole and specific protocols that must be followed before it becomes a jab.
If Australians won’t take the AstraZeneca vaccine, we must donate it to save lives elsewhere, especially while we queue-jump for more Pfizer doses.
South Africa has clearly suffered the consequences of poor strategic decisions to this point. It doesn’t need to continue along these lines.
World leaders have called for an end to the pandemic – but the numbers don’t add up.
The high costs of the world’s colossally unequal COVID-19 immunization rates.
Local companies in Africa would find it very challenging to be cost-competitive in the longer run when the current worldwide scarcity of COVID-19 vaccines is overcome.
Covax was doomed to failure from the start. It is already running into three major problems.
The inefficient vaccine allocation rules currently in place must be replaced by new cooperative institutional structures and more concrete steps by the Group of Twenty (G20) countries.
If there ever was a global health system, then it has gone sadly missing when we needed it most.
Scientific knowledge is a critical driver for human health and wellbeing, economic development and environmental sustainability.
Despite some public virtue signalling, the Canadian government is not doing all it can to improve global access to COVID-19 vaccines. Canada has yet to announce its position on the WTO patent waiver.
Increased demand and falling supplies in India risk leaving many countries empty handed.
Top contributors
-
Associate Professor in Public Health, La Trobe University
-
Executive Director, African Population and Health Research Center
-
Professor and Distinguished Research Chair, Globalization and Health Equity, L’Université d’Ottawa/University of Ottawa
-
Dean Faculty of Health Sciences and Professor of Vaccinology at University of the Witwatersrand; and Director of the SAMRC Vaccines and Infectious Diseases Analytics Research Unit, University of the Witwatersrand
-
Associate Principal Research Fellow, Burnet Institute
-
Professor of International Politics, Queen Mary University of London
-
Professor of Philosophy, Binghamton University, State University of New York
-
Senior Lecturer, Global Development Institute, University of Manchester
-
Part-time lecturer at the Global Health & Social Medicine, Harvard University, and Lecturer at the School of Public Health, College of Health Sciences, University of Liberia
-
Senior Scholar with the Global Health Policy & Politics Initiative at the O’Neill Institute, Georgetown University
-
Professor of Human Rights Law, Griffith University
-
Professor in Infectious Diseases Epidemiology, Monash University
-
Senior Technical Advisor - HIV, The Nossal Institute for Global Health, PhD candidate La Trobe University, The University of Melbourne
-
Associate Professor, Newcastle Business School, University of Newcastle
-
Associate professor, University of Sydney
